Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 1/2015

Open Access 01-03-2015 | Original Article

Urine l-carnitine excretion in hypertensive adolescents

Authors: A. Kępka, E. Kuroczycka-Saniutycz, S. Chojnowska, R. Fiłonowicz, A. Korzeniecka-Kozerska, A. Wasilewska

Published in: Irish Journal of Medical Science (1971 -) | Issue 1/2015

Login to get access

Abstract

Aim

This study was performed to test the hypothesis that urinary levels of l-carnitine and its derivatives are enhanced in children and adolescents with hypertension and also check if analyzed parameters may serve as early markers of subclinical renal damage.

Methods

The study included 112 children and adolescents (67 males and 45 females) aged median 10–18 years. Participants were divided into two groups: HT—64 subjects with confirmed primary hypertension and R—reference group—48 subjects with white-coat hypertension.
Urinary Free and Total l-carnitine were determined by the enzymatic method of Cederblad. The l-carnitine levels were expressed as urinary ratio in micromole per gram creatinine (μmol/g).

Results

The urinary excretion of Total and Free l-carnitine was significantly higher in hypertensive adolescents in comparison to reference group—white coat hypertension. Other important findings were positive correlations between Free l-carnitine/cr., Total l-carnitine/cr. ratio and serum uric acid level, serum cholesterol level and systolic blood pressure.

Conclusion

The results of this study do not explain the increased urine levels of l-carnitine. The most likely reason for excessive urinary loss was disturbed renal tubular reabsorption. It is possible to hypothesize that in hypertensive adolescents subclinical kidney dysfunction occurs. It is proposed that studies examining the concurrent plasma and urine concentration of l-carnitine and correlation with acknowledged proximal tubular markers are needed.
Literature
1.
go back to reference Perlstein TS, Gumieniak O, Williams GH et al (2006) Uric acid and the development of hypertension: the normative aging study. Hypertension 48:1031–1036CrossRefPubMed Perlstein TS, Gumieniak O, Williams GH et al (2006) Uric acid and the development of hypertension: the normative aging study. Hypertension 48:1031–1036CrossRefPubMed
3.
go back to reference Feig DI, Kang DH, Nakagawa T et al (2006) Uric acid and hypertension. Curr Hypertens Rep 8:111–115CrossRefPubMed Feig DI, Kang DH, Nakagawa T et al (2006) Uric acid and hypertension. Curr Hypertens Rep 8:111–115CrossRefPubMed
4.
go back to reference Mellen PB, Bleyer AJ, Erlinger TP et al (2006) Serum uric acid predicts incident hypertension in a biethnic cohort. Hypertension 48:1037–1042CrossRefPubMed Mellen PB, Bleyer AJ, Erlinger TP et al (2006) Serum uric acid predicts incident hypertension in a biethnic cohort. Hypertension 48:1037–1042CrossRefPubMed
5.
go back to reference Selby JV, Friedman GD, Quesenberry CP (1990) Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 131:1017–1027PubMed Selby JV, Friedman GD, Quesenberry CP (1990) Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 131:1017–1027PubMed
6.
go back to reference Arduini A, Bonomini M, Savica V et al (2008) Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 120:149–156CrossRefPubMed Arduini A, Bonomini M, Savica V et al (2008) Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 120:149–156CrossRefPubMed
7.
go back to reference Emami Naini A, Moradi M, Mortazavi M et al (2012) Effects of oral l-carnitine supplementation on lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: a randomized, double-blinded, placebocontrolled trial. J Nutr Metab 2012(510483):1–6. doi:10.1155/2012/510483 CrossRef Emami Naini A, Moradi M, Mortazavi M et al (2012) Effects of oral l-carnitine supplementation on lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: a randomized, double-blinded, placebocontrolled trial. J Nutr Metab 2012(510483):1–6. doi:10.​1155/​2012/​510483 CrossRef
8.
go back to reference Ruggenenti P, Cattaneo D, Loriga G et al (2009) Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-l-carnitine therapy. Hypertension 54:567–574CrossRefPubMed Ruggenenti P, Cattaneo D, Loriga G et al (2009) Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-l-carnitine therapy. Hypertension 54:567–574CrossRefPubMed
9.
go back to reference Bremer J (1983) Carnitinemetabolism and functions. Physiol Rev 63:1420–1480PubMed Bremer J (1983) Carnitinemetabolism and functions. Physiol Rev 63:1420–1480PubMed
10.
go back to reference Zambrano S, Blanca AJ, Ruiz-Armenta MV, et al. (2012) The renoprotective effect of l-carnitine in hypertensive rats is mediated by modulation of oxidative stress-related gene expression. Eur J Nutr 1-11. doi:10.1007/s00394-012-0470-x Zambrano S, Blanca AJ, Ruiz-Armenta MV, et al. (2012) The renoprotective effect of l-carnitine in hypertensive rats is mediated by modulation of oxidative stress-related gene expression. Eur J Nutr 1-11. doi:10.​1007/​s00394-012-0470-x
11.
go back to reference Rebouche CJ, Paulson DJ (1986) Carnitine metabolism and function in humans. Annu Rev Nutr 6:41–66CrossRefPubMed Rebouche CJ, Paulson DJ (1986) Carnitine metabolism and function in humans. Annu Rev Nutr 6:41–66CrossRefPubMed
12.
go back to reference Foster KA, O’Rourke B, Reibel DK (1985) Altered carnitine metabolism in spontaneously hypertensive rats. Am J Physiol 249(2 Pt 1):E183–E186PubMed Foster KA, O’Rourke B, Reibel DK (1985) Altered carnitine metabolism in spontaneously hypertensive rats. Am J Physiol 249(2 Pt 1):E183–E186PubMed
13.
go back to reference Urbina E, Alpert B, Flynn J et al (2008) American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension 52:433–451CrossRefPubMed Urbina E, Alpert B, Flynn J et al (2008) American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension 52:433–451CrossRefPubMed
14.
go back to reference Cederblad G, Harper P, Lindgren K (1986) Spectrophotometry of carnitine in biological fluids and tissue with cobas bio centrifugal analyzer. Clin Chem 32(2):342–346PubMed Cederblad G, Harper P, Lindgren K (1986) Spectrophotometry of carnitine in biological fluids and tissue with cobas bio centrifugal analyzer. Clin Chem 32(2):342–346PubMed
15.
go back to reference Wühl E, Witte K, Soergel M et al (2002) German Working Group on Pediatric Hypertension Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 20:1995–2007CrossRefPubMed Wühl E, Witte K, Soergel M et al (2002) German Working Group on Pediatric Hypertension Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 20:1995–2007CrossRefPubMed
16.
17.
go back to reference Miguel-Carrasco JL, Mate A, Monserrat MT et al (2008) The role of inflammatory markers in the cardioprotective effect of l-carnitine in l-NAME-induced hypertension. Am J Hypertens 21(11):1231–1237. doi:10.1038/ajh.2008.271 CrossRefPubMed Miguel-Carrasco JL, Mate A, Monserrat MT et al (2008) The role of inflammatory markers in the cardioprotective effect of l-carnitine in l-NAME-induced hypertension. Am J Hypertens 21(11):1231–1237. doi:10.​1038/​ajh.​2008.​271 CrossRefPubMed
18.
go back to reference Omori Y, Ohtani T, Sakata Y et al (2012) l-carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens 30(9):1834–1844CrossRefPubMed Omori Y, Ohtani T, Sakata Y et al (2012) l-carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens 30(9):1834–1844CrossRefPubMed
21.
go back to reference Ahmad S Carnitine, kidney and renal dialysis. In: Ferrari R, DiMauro S, Sherwood G, editors. l-carnitine and its role in medicine: from function to therapy. New York: Academic Press 1992: 381-400 Ahmad S Carnitine, kidney and renal dialysis. In: Ferrari R, DiMauro S, Sherwood G, editors. l-carnitine and its role in medicine: from function to therapy. New York: Academic Press 1992: 381-400
22.
go back to reference Heuberger W, Berardi S, Jacky E et al (1998) Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 54(7):503–508CrossRefPubMed Heuberger W, Berardi S, Jacky E et al (1998) Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 54(7):503–508CrossRefPubMed
23.
24.
go back to reference Nezu J-I, Tamai I, Oku A et al (1999) Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 21(1):91–94CrossRefPubMed Nezu J-I, Tamai I, Oku A et al (1999) Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 21(1):91–94CrossRefPubMed
25.
go back to reference Tamai I, Ohashi R, Nezu J- et al (1998) Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273(32):20378–20382CrossRefPubMed Tamai I, Ohashi R, Nezu J- et al (1998) Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273(32):20378–20382CrossRefPubMed
27.
go back to reference Mancinelli A, Longo A, Shanahan K et al (1995) Disposition of l-carnitine and acetyl-l-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther 274(3):1122–1128PubMed Mancinelli A, Longo A, Shanahan K et al (1995) Disposition of l-carnitine and acetyl-l-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther 274(3):1122–1128PubMed
28.
go back to reference Famularo G, De SC, Trinchieri V et al (2004) Carnitines and its congeners: a metabolic pathway to the regulation of immune response and inflammation. Ann NY Acad Sci 1033:132–138CrossRefPubMed Famularo G, De SC, Trinchieri V et al (2004) Carnitines and its congeners: a metabolic pathway to the regulation of immune response and inflammation. Ann NY Acad Sci 1033:132–138CrossRefPubMed
29.
go back to reference Izgut-Uysal VN, Agac A, Derin N (2003) Effect of Lcarnitine on carrageenan-induced inflammation in aged rats. Gerontology 49:287–292CrossRefPubMed Izgut-Uysal VN, Agac A, Derin N (2003) Effect of Lcarnitine on carrageenan-induced inflammation in aged rats. Gerontology 49:287–292CrossRefPubMed
30.
go back to reference Vescovo G, Ravara B, Gobbo V et al (2002) l-carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am J Physiol Cell Physiol 283:C802–C810CrossRefPubMed Vescovo G, Ravara B, Gobbo V et al (2002) l-carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am J Physiol Cell Physiol 283:C802–C810CrossRefPubMed
31.
go back to reference Rajasekar P, Viswanathan P, Anuradha CV (2008) Renoprotective action of l-carnitine in fructose-induced metabolic syndrome. Diabetes Obes Metab 10:171–180CrossRefPubMed Rajasekar P, Viswanathan P, Anuradha CV (2008) Renoprotective action of l-carnitine in fructose-induced metabolic syndrome. Diabetes Obes Metab 10:171–180CrossRefPubMed
32.
go back to reference Corry DB, Eslami P, Yamamoto K et al (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J Hypertens 26:269–275CrossRefPubMed Corry DB, Eslami P, Yamamoto K et al (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J Hypertens 26:269–275CrossRefPubMed
33.
go back to reference Kang DH, Nakagawa T, Feng L et al (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888–2897CrossRefPubMed Kang DH, Nakagawa T, Feng L et al (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888–2897CrossRefPubMed
34.
go back to reference Mazzali M, Kanellis J, Han L et al (2002) Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282:F991–F997CrossRefPubMed Mazzali M, Kanellis J, Han L et al (2002) Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282:F991–F997CrossRefPubMed
35.
go back to reference Yu MA, Sánchez-Lozada LG, Johnson RJ et al (2010) Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid -induced endothelial dysfunction. J Hypertens 28:1234–1242PubMed Yu MA, Sánchez-Lozada LG, Johnson RJ et al (2010) Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid -induced endothelial dysfunction. J Hypertens 28:1234–1242PubMed
36.
go back to reference Ryu ES, Kim MJ, Shin HS et al (2013) Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304:F471–F480CrossRefPubMed Ryu ES, Kim MJ, Shin HS et al (2013) Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304:F471–F480CrossRefPubMed
Metadata
Title
Urine l-carnitine excretion in hypertensive adolescents
Authors
A. Kępka
E. Kuroczycka-Saniutycz
S. Chojnowska
R. Fiłonowicz
A. Korzeniecka-Kozerska
A. Wasilewska
Publication date
01-03-2015
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 1/2015
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-014-1091-6

Other articles of this Issue 1/2015

Irish Journal of Medical Science (1971 -) 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.